Miami, FL -- (ReleaseWire) -- 07/17/2014 -- GrowBLOX Sciences, Inc. a medical marijuana research and development company, is pleased to announce it has entered the Florida Medical Marijuana Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 million residents, Florida is poised to be the biggest medical marijuana market outside of California. The National Cannabis Industry Association estimates medical marijuana will be a $785 million industry in Florida with multiple economic opportunities. In November, Florida voters will decide if they should allow widespread sale and use of medical cannabis by saying "yay" or "nay" on The Florida Right to Medical Marijuana Initiative, commonly known as Amendment 2. Early polls show that voters are likely to approve the ballot as all expectations are for a landslide approval. If and when Florida approves the bill, it will become the first state in the Southeast to do so.
Furthermore, GrowBLOX Sciences recognizes Florida's high standards for quality in medical marijuana cultivation as a perfect match for their GrowBLOX™ cultivation technology. GrowBLOX CEO, Craig Ellins, said, "In an effort to safeguard Florida's medical marijuana patients, Florida's legislators have crafted some of the country's most stringent quality standards when it comes to the safety and efficacy of the medical marijuana grown in their state. They want medical solutions, and that's exactly what our GrowBLOX™ does, it makes medicine."
The GrowBLOX™ cultivation chamber is uniquely designed to produce medical marijuana with consistent potency from harvest to harvest. Medical marijuana grown in our GrowBLOX™ is also completely shielded from harmful pesticides, insecticides, and other pollutants. This provides medical marijuana patients with peace of mind knowing that they are receiving the same quality and quantity of active compounds within our medicinal marijuana with each use. Mr. Ellins made this comparison, "Think of when you buy a bottle of over the counter medication. Whether you buy that medication in New York or Texas, you know that you are getting the exact same medication no matter where or when you buy it. That is the idea behind the GrowBLOX™ cultivation system. Plants grown through other grow conditions will have harvest to harvest inconsistencies. We want our customers to know that they are getting the same medicine each and every time."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and development company that has proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOX™ chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Riverview Capital Enterprises